This study will evaluate the efficacy, safety, participant choice and preference of an oral once daily treatment or a long acting injectable regimen every two months for the treatment of HIV-1 in adults who have not previously taken medications for HIV infection.
This study is a clinical trial for adults infected with HIV-1 who have not yet been started on HIV medications. It is a non randomized and open label study, which means everyone involved with the study, including the participant will know what drug they are taking. The drugs used in this study have already been approved by the FDA and have already been studied in other clinical trials. They are known to be safe and effective. If the participant meets all entry criteria they will be started on a drug called Dovato, a pill taken once a day for the treatment of HIV. Once the HIV virus is suppressed to a level where it is undetectable on a lab test, the subject will have a choice of staying on the Dovato, or switching to a long acting injectable HIV medication called Cabenuva, which is injected every 2 months, or remaining on the Dovato.
Study procedures involve visits to the research office, lab tests, EKG, surveys and questionnaires. The study will last approximately one year and whatever medications the participant chooses will be provided free of charge as part of study participation.
Male or Female adults 18 and over newly diagnosed with HIV-1 who have not yet been started on HIV medicines. Females who are pregnant, plan to become pregnant, or are breastfeeding will not be enrolled. Participants will have blood tests done and an EKG as part of the study and the results will need to meet study criteria for participation.
Please contact the Network Office of Research and Innovation at 610-402-9543.
1627 W Chew Street
Third Floor
Allentown, PA 18102-3648
United States